Ranbaxy Laboratories plans to appeal against the EU commission's decision

20 Jun 2013 Evaluate

Ranbaxy Laboratories is disappointed with the Decision by the European Commission to rule its patent settlement agreement with Lundbeck, covering the molecule Citalopram, anti-competitive, and intends to appeal the Decision to the General Court of the European Union (EU). These events took place over ten years ago, and the company considers that the Commission has misunderstood the facts and misapplied the law. The company  believes it has strong grounds of appeal. Ranbaxy respects, and is committed to conducting its business in compliance with, European law, and is dedicated to offering high quality, affordable medicines for the benefit of patients, prescribers, customers and the European healthcare system.

Ranbaxy Laboratories, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Peers
Company Name CMP
Sun Pharma Inds. 1729.95
Dr. Reddys Lab 1209.45
Cipla 1466.15
Zydus Lifesciences 894.95
Lupin 2181.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×